查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1702365

全球基因检测市场 - 2025-2033

Global Genetic Testing Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年全球基因检测市场规模达147.2亿美元，预计到2033年将达到542.1亿美元，在2025-2033年的预测期内复合年增长率为15.4%。

全球基因检测市场是指使用分析 DNA、RNA 或蛋白质的诊断测试来识别遗传状况、遗传疾病和未来健康状况的风险。该市场包括各种类型的基因测试，例如携带者测试、诊断测试、预测测试、产前测试和药物基因组学。这些测试有助于诊断疾病、了解遗传倾向并制定个人化治疗策略。

基因检测可以实现个人化治疗策略，根据个人基因特征客製化医疗保健。它有助于早期诊断，透过确定最佳治疗方案和避免不良药物反应来改善患者的治疗效果。

市场动态：

驾驶员和约束装置

遗传性疾病和慢性病盛行率不断上升

遗传疾病和慢性病的日益普及预计将极大地推动基因检测市场的成长。随着囊性纤维化、镰状细胞性贫血和亨廷顿氏症等遗传疾病的发生率不断上升，对基因检测的需求也在增加。例如，根据囊性纤维化基金会的数据，每年约有 1,000 例新的 CF 病例被诊断出来。每年数量的增加都增加了对先进检测程序的需求，以便在早期诊断病情。

透过基因检测进行早期发现可以帮助医疗保健提供者提供个人化的治疗方案，从而有可能改善治疗效果并从长远来看降低医疗保健成本。此外，癌症、糖尿病和心血管疾病等慢性疾病的发生率不断上升，进一步增加了基因检测的需求。

许多患有慢性疾病的人都被要求进行基因检测或对此感兴趣，以便准确诊断疾病。例如，根据芝加哥大学 NORC 2022 年的调​​查，17% 的美国人实际上已经接受过基因检测，52% 的人表示对此类检测感兴趣。因此，预计上述因素将推动市场成长。

基因检测和定序技术成本高昂

基因检测和定序技术的高成本预计将成为基因检测市场成长的重大障碍。儘管基因检测取得了进步，但与次世代定序 (NGS) 等定序技术相关的费用仍然相对较高，使得很大一部分人无法负担这些检测的费用。

高昂的成本可能会限制人们获得基因检测的机会，特别是对于已开发市场和新兴市场中服务不足的人。例如，许多人可能无法负担疾病风险评估、产前筛检或个人化医疗的测试，这可能会阻碍早期诊断或个人化治疗计划，而这些计划可以显着改善健康结果。

因此，基因检测和定序技术的高成本可能会限制可及性和减少需求，从而阻碍市场的成长。因此，上述因素可能会限制全球基因检测市场的潜在成长。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的程式码片段
  • 技术片段
  • 按测试类型分类的程式码片段
  • 按应用程式截取的程式码片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 遗传性疾病和慢性病盛行率不断上升
      • 下一代定序 (NGS) 和 PCR 技术的进展
    • 限制
      • 基因检测和定序技术成本高昂
      • 关于基因数据的伦理和隐私问题
    • 机会
      • 具有尚未开发的成长潜力的新兴市场
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：基因检测市场（依产品类型）

  • 耗材
  • 装置
  • 软体

第六章：基因检测市场（依技术）

  • 下一代定序（NGS）
  • 聚合酶炼式反应（PCR）
  • 萤光原位杂交（FISH测试）
  • 其他的

第七章：基因检测市场（依检测类型）

  • 携带者检测
  • 产前和新生儿检测
  • 植入前检查
  • 预测性和症状前检测
  • 法医检测
  • 诊断测试
  • 其他的

第 8 章：基因检测市场（按应用）

  • 癌症诊断
  • 遗传疾病诊断
  • 心血管疾病诊断
  • 其他的

第九章：基因检测市场，依区域市场分析与成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第十章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第 11 章：公司简介

    • 雅培实验室
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • BioRad实验室公司
  • Illumina公司
  • Myriad Genetics公司
  • 丹纳赫公司
  • Quest Diagnostics公司
  • 医学基因组
  • LabCorp
  • 3billion公司
  • 蓝图遗传学

第 12 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 13 章：附录

简介目录
Product Code: BT226

The global genetic testing market reached US$ 14.72 billion in 2024 and is expected to reach US$ 54.21 billion by 2033, growing at a CAGR of 15.4 % during the forecast period of 2025-2033.

The global genetic testing market refers to the use of diagnostic tests that analyze DNA, RNA, or proteins to identify genetic conditions, hereditary diseases, and the risk of future health conditions. This market includes various types of genetic tests, such as carrier testing, diagnostic testing, predictive testing, prenatal testing, and pharmacogenomics. These tests help in diagnosing diseases, understanding genetic predispositions, and enabling personalized treatment strategies.

Genetic testing allows for personalized treatment strategies, tailoring healthcare to individual genetic profiles. It aids in early diagnosis, improving patient outcomes by identifying the best treatment options and avoiding adverse drug reactions.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Genetic Disorders and Chronic Diseases

The increasing prevalence of genetic disorders and chronic diseases is expected to significantly drive the growth of the genetic testing market. As the incidence of genetic conditions like cystic fibrosis, sickle cell anemia, and Huntington's disease continues to rise, the demand for genetic testing is also growing. For instance, according to the Cystic Fibrosis Foundation, approximately 1,000 new cases of CF are diagnosed each year. This increase in the number every year increases the demand for advanced testing procedures to diagnose the condition at an early stage.

Early detection through genetic testing can help healthcare providers offer personalized treatment plans, potentially improving outcomes and reducing healthcare costs in the long run. In addition, the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is increasing the need for genetic testing even more.

A large number of individuals suffering from chronic diseases are prescribed or are showing interest in genetic testing to diagnose the disease accurately. For instance, according to the NORC at the University of Chicago in 2022, it is stated that 17 percent of Americans have actually undergone genetic testing, and 52 percent report interest in such a test. Thus, the above factors are expected to drive the market growth.

High Cost of Genetic Tests and Sequencing Technologies

The high cost of genetic tests and sequencing technologies is expected to be a significant barrier to the growth of the genetic testing market. Despite advancements in genetic testing, the expenses associated with sequencing technologies, such as next-generation sequencing (NGS), remain relatively high, making these tests unaffordable for a large portion of the population.

This high cost can limit access to genetic testing, particularly for underserved populations in both developed and emerging markets. For example, many individuals may be unable to afford tests for disease risk assessment, prenatal screening, or personalized medicine, which could prevent early diagnosis or personalized treatment plans that could significantly improve health outcomes.

As a result, the high cost of genetic tests and sequencing technologies is likely to hinder the market's growth by limiting accessibility and reducing demand. Thus, the above factors could be limiting the global genetic testing market's potential growth.

Segment Analysis

The global genetic testing market is segmented based on product type, technology, testing type, application, and region.

Technology:

The next-generation sequencing (NGS) segment in technology is expected to dominate the global genetic testing market with the highest market share

Next-Generation Sequencing (NGS) is a transformative technology in the genetic testing market, enabling the rapid and cost-effective sequencing of DNA and RNA. It is widely used in various applications, including clinical diagnostics, oncology, precision medicine, biomarker discovery, and agriculture. The global NGS market is experiencing strong growth, driven by advancements in sequencing technology, decreasing costs, and increasing demand for personalized medicine and genetic research.

For instance, in February 2025, Devyser launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution aimed at improving the accuracy and efficiency of genetic testing for alpha and beta thalassemia. This new version enhances the detection of structural variants and copy number variations (CNVs), providing broader and more precise screening capabilities. This innovation aligns with the growing demand for high-accuracy genetic diagnostics, particularly in the expanding NGS segment in the market.

Geographical Analysis

North America is expected to hold a significant position in the global genetic testing market, with the highest market share

North America is expected to dominate the genetic testing market due to various significant factors. The growing prevalence of chronic diseases, and genetic disorders in North America fuels the demand for genetic testing. As more individuals are diagnosed with conditions such as diabetes, cancer, and hereditary diseases, there is a growing demand for genetic testing to help in early diagnosis, risk assessment, and personalized treatment planning.

For instance, according to the report by the American Cancer Society in 2025, it is stated that approximately 1 in 8 women in the United States are diagnosed with breast cancer. Being one of the common cancers among women, the need for genetic testing is expected to increase, which is expected to drive the genetic testing market. Genetic testing detects inherited genetic mutations for various cancers.

Companies in the region are mainly focusing on developing advanced solutions for the diagnosis of genetic diseases to help in identifying the mutations in the genes and help in developing personalized medicine. For instance, in March 2024, Nucleus Genomics, a next-generation genetic testing and analysis company, launched its DNA analysis product aimed at making the benefits of personalized medicine accessible to everyone. This product is designed to empower individuals with the knowledge of their genetic makeup, helping them make informed decisions about their health.

Moreover, North America has one of the highest adoption rates of personalized medicine, where genetic tests play a crucial role in tailoring treatments to individual patients based on their genetic makeup. Thus, various factors are contributing to the region's dominant position in the global genetic testing market.

Competitive Landscape

The major global players in the genetic testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Myriad Genetics Inc., Danaher Corporation, Quest Diagnostics Incorporated, MedGenome, LabCorp, 3billion, Inc., and Blueprint Genetics, among others.

Key Developments

  • In August 2024, Nonacus launched the GALEAS Tumor test, a comprehensive genomic profiling (CGP) solution designed to analyze tumor genetics using next-generation sequencing (NGS). This test integrates bioinformatics and analysis software, making it easier for clinicians to detect genetic mutations linked to various cancers, including rare and complex ones like brain tumors.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global genetic testing market report delivers a detailed analysis with 70 key tables, more than 68 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Testing Type
  • 2.6. Snippet by Application
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Prevalence of Genetic Disorders and Chronic Diseases
      • 3.1.1.2. Advances In Next-Generation Sequencing (NGS) and PCR Technologies
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Genetic Tests and Sequencing Technologies
      • 3.1.2.2. Ethical and Privacy Concerns Regarding Genetic Data
    • 3.1.3. Opportunity
      • 3.1.3.1. Emerging Markets with Untapped Growth Potential
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Genetic Testing Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index By Product Type
  • 5.2. Consumables*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Equipment
  • 5.4. Software

6. Genetic Testing Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index By Technology
  • 6.2. Next-Generation Sequencing (NGS)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Polymerase Chain Reaction (PCR)
  • 6.4. Fluorescence in Situ Hybridization (FISH Test)
  • 6.5. Others

7. Genetic Testing Market, By Testing Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 7.1.2. Market Attractiveness Index By Testing Type
  • 7.2. Carrier Testing*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Prenatal and Newborn Testing
  • 7.4. Preimplantation Testing
  • 7.5. Predictive and presymptomatic testing
  • 7.6. Forensic testing
  • 7.7. Diagnostic Testing
  • 7.8. Others

8. Genetic Testing Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer Diagnosis*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Genetic Disease Diagnosis
  • 8.4. Cardiovascular Disease Diagnosis
  • 8.5. Others

9. Genetic Testing Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

    • 11.1.1. Abbott Laboratories*
    • 11.1.2. Company Overview
    • 11.1.3. Product Portfolio
      • 11.1.3.1. Product Description
      • 11.1.3.2. Product Key Performance Indicators (KPIs)
      • 11.1.3.3. Historic and Forecasted Product Sales
      • 11.1.3.4. Product Sales Volume
    • 11.1.4. Financial Overview
      • 11.1.4.1. Company Revenue
      • 11.1.4.2. Geographical Revenue Shares
      • 11.1.4.3. Revenue Forecasts
    • 11.1.5. Key Developments
      • 11.1.5.1. Mergers & Acquisitions
      • 11.1.5.2. Key Product Development Activities
      • 11.1.5.3. Regulatory Approvals, etc.
    • 11.1.6. SWOT Analysis
  • 11.2. BioRad Laboratories Inc
  • 11.3. Illumina Inc
  • 11.4. Myriad Genetics Inc
  • 11.5. Danaher Corporation
  • 11.6. Quest Diagnostics Incorporated
  • 11.7. MedGenome
  • 11.8. LabCorp
  • 11.9. 3billion, Inc
  • 11.10. Blueprint Genetics

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us